Sells FDA-cleared, wearable-based exercise therapy programs to employers and health plans for treating musculoskeletal injuries.
At a glance
- Depends onMidstream position: 4 outgoing, 6 incoming connections
- Scale
Sells FDA-cleared, wearable-based exercise therapy programs to employers and health plans for treating musculoskeletal injuries.
What this company is and how it runs — written from structure, not news.
Hinge Health sells physical therapy programs to employers and health plans, delivered through a wearable motion sensor that tracks how patients move during exercise and feeds that data into a correction algorithm trained on the clinical trial cohort for each specific musculoskeletal condition. Each of those trials is what generated the FDA clearance for that condition's protocol, so the sensor data, the algorithm, and the regulatory approval are a single stack that cannot be reassembled from scratch by a competitor who simply copies the hardware. Once an employer or health plan integrates the cleared protocols into their benefits and claims systems, switching to an uncleared alternative would expose them to regulatory and workers' compensation liability they are not permitted to accept, which is what keeps the contracts in place. The one thing that cannot be accelerated is expansion into new conditions — each requires its own controlled clinical trial with a specific patient population, so the pace of growth is set by trial timelines rather than by engineering capacity or commercial demand.
How does this company make money?
Employers and health plans pay a recurring monthly fee for each employee or member who has access to the musculoskeletal therapy programs. On top of that, the company charges additional fees for implementation and clinical support services when a new employer or health plan gets set up.
What makes this company hard to replace?
Patient biometric data and exercise progression histories are already wired into employer wellness platforms and health plan member portals through API integrations, so pulling them out is not straightforward. Clinical staff have been trained on the biomechanical assessment protocols, creating real workflow dependencies. And because the therapy protocols carry FDA clearance, substituting a non-validated alternative would expose employers and health plans to regulatory and liability risks they cannot take on, especially for workers' compensation populations.
What limits this company?
Every new musculoskeletal condition or protocol variation needs its own controlled clinical trial before the company can apply for FDA clearance. Those trials require specific patient populations that money alone cannot assemble faster. No matter how ready the engineering or sales teams are, new therapy programs have to wait in line behind trial timelines.
What does this company depend on?
The company cannot operate without five things: the FDA De Novo classification pathway for digital therapeutic devices, which is the legal basis for every cleared protocol; the manufacturing supply chain for its proprietary motion sensor hardware; clinical partnerships with physical therapy providers, whose patients supply the trial cohorts used to validate each protocol; employer benefits administration platforms, which handle member enrollment; and HIPAA-compliant cloud infrastructure to process patient biometric data.
Who depends on this company?
Self-insured employers rely on it to manage workers' compensation costs — without access to remote musculoskeletal care, injured employees have fewer options and claims costs rise. Health plans depend on it to keep members out of expensive in-person physical therapy or orthopedic procedures; when those members cannot access digital alternatives, the share of premiums spent on medical claims gets worse.
How does this company scale?
The software-based exercise protocols and movement analysis algorithms can be delivered to an unlimited number of additional patients at almost no extra cost — that part scales easily. What does not scale on demand is the clinical validation process: each new musculoskeletal condition still requires a controlled trial with a specific patient population, and no amount of additional spending can compress that timeline.
What external forces can significantly affect this company?
Medicare Advantage star ratings now give more weight to how well members can access musculoskeletal care, which pushes health plans toward adopting digital therapy programs. The shift to remote work after 2020 made employers more focused on preventing repetitive strain injuries in distributed workforces. CMS expanding reimbursement for digital therapeutics is drawing traditional rehabilitation providers into the same space, increasing competition.
Where is this company structurally vulnerable?
If the FDA revised the De Novo classification criteria for digital therapeutic devices and required post-market outcome benchmarks that the existing trial designs never measured, every cleared protocol would need to be re-validated in its own separate trial. That would dismantle the cleared-protocol library that makes the company hard to copy, leaving only the hardware and software — things a well-funded competitor could eventually match.
Price is read as structure — trend, levels, range, peak and volatility drawn on the chart. It does not predict where price goes next.
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Shared structure with peers — never a ranking.
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Companies that share the same coordination system — how they create, deliver, or capture value.
CompanyGraph